Your Article Summary
See Latest ArticlesA large randomized controlled trial (RCT) is needed to provide a reliable answer as to whether acetylcysteine is effective in decreasing the risk of CIN in high-risk patients undergoing angiographic procedures. The mean age was 69, 18% had a baseline serum creatinine >1.5mg/dL, 57% were diabetics and 13% had a history of heart failure. The ongoing ACT Trial is the largest multicentre RCT that will determine whether acetylcysteine is effective in decreasing the risk of CIN in patients at risk undergoing angiography.
Related Articles
Nephropathy in Type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity
Platelets, 10/30/09
Relevance Score: 91%
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)
Nephrology Dialysis Transplantation, 10/16/09
Relevance Score: 90%
Renal Cell Carcinoma in Association With IgA Nephropathy in the Elderly
The American Journal of the Medical Sciences, 11/13/09
Relevance Score: 89%
Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetes
Diabetes Care, 10/28/09
Relevance Score: 89%
DNase1 activity in systemic lupus erythematosus patients with and without nephropathy
Rheumatology International, 10/26/09
Relevance Score: 89%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09